MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
Shunsuke Kitajima(Japanese Foundation For Cancer Research), David A. Barbie(Dana-Farber Cancer Institute), Mizuki Homme(Japanese Foundation For Cancer Research), Connor Purcell(Dana-Farber Cancer Institute), Erik H. Knelson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ryohei Yoshida(Asahikawa Medical University), Sophie Kivlehan(Dana-Farber Cancer Institute), Benjamin F. Springer(Dana-Farber Cancer Institute), Marco Campisi(Dana-Farber Cancer Institute), Tetsuo Tani(Keio University), Minyue Chen(Dana-Farber Cancer Institute), Bonje Obua(Dana-Farber Cancer Institute), Tatsuya Osaki(Whitehead Institute for Biomedical Research), Ryu‐Suke Nozawa(Japanese Foundation For Cancer Research), Shriram K. Sundararaman(Beth Israel Deaconess Medical Center), Pasi A. Jänne(Harvard University), Brandon Piel(Dana-Farber Cancer Institute), Thanh U. Barbie(Brigham and Women's Hospital), Cloud P. Paweletz(Massachusetts General Hospital), Tran C. Thai(Dana-Farber Cancer Institute), Jessica Ritter(Dana-Farber Brigham Cancer Center), Koji Haratani(Dana-Farber Cancer Institute), Patrick H. Lizotte(Harvard University), Jens Köhler(Dana-Farber Cancer Institute), Prafulla C. Gokhale(Harvard University), Mamiko Yajima(Brown University), Navin R. Mahadevan(Brigham and Women's Hospital), Atsuko Ogino(Dana-Farber Cancer Institute)
Cited by 101
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k